<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756223</url>
  </required_header>
  <id_info>
    <org_study_id>1257.1</org_study_id>
    <secondary_id>2008-001631-36</secondary_id>
    <nct_id>NCT00756223</nct_id>
  </id_info>
  <brief_title>Phase I Study of BI 831266 in Patients With Advanced Solid Tumours</brief_title>
  <official_title>An Open-label Phase I Single Dose Escalation Trial of Two Dosing Schedules of BI 831266 Administered Intravenously Over 24 h Continuously in Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The main objective of this trial is to provide safety data in terms of drug-related adverse
      events for the recommendation of the dose for further trials in the development of BI 831266.

      Secondary objectives are the collection of antitumour efficacy data and the determination of
      the pharmacokinetic and pharmacodynamic profile of BI 831266.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>3-4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety parameters (incidence and intensity of AEs graded according to the common terminology criteria for AEs and incidence of DLT)</measure>
    <time_frame>throughout the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>throughout the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic analysis</measure>
    <time_frame>3-4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy data (progression free survival, objective response rate, response duration)</measure>
    <time_frame>throughout the study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 831266 24h infusion on day 1 and day 15 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 831266 24h infusion on day 1 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm A</intervention_name>
    <description>Dose escalation Arm A (4 weeks)</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm B</intervention_name>
    <description>Dose escalation Arm B (3 weeks)</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with confirmed diagnosis of advanced, non-resectable and/or metastatic solid
             malignant tumours, who have failed conventional treatment or for whom no therapy of
             proven efficacy exists or who are not amenable to established treatment options

          2. Secure central venous access

          3. Measurable and/or non-measurable tumour deposits

          4. Recovery from toxicities of prior anti-cancer therapies at least to CTCAE grade 1

          5. Age &gt;= 18 years

          6. Life expectancy &gt;= 3 months

          7. Written informed consent in accordance with International Conference on Harmonisation
             guideline for Good Clinical Practice and local legislation

          8. Eastern Cooperative Oncology Group performance score &lt;= 2

        Exclusion criteria:

          1. Serious illness, concomitant non-oncological disease (e.g. active infectious disease),
             or ongoing toxicity of prior therapies considered by the investigator to potentially
             compromise patients' safety in this trial

          2. Pregnancy or breastfeeding

          3. Symptomatic brain metastases and/or leptomeningeal disease requiring therapy

          4. Second malignancy requiring therapy

          5. Left ventricular ejection fraction (LVEF) &lt; 50% in echocardiography

          6. Clinically significant (i.e. active) cardiovascular disease: CVA/stroke (&lt;= 6 months
             prior to randomisation), myocardial infarction (&lt;= 6 months prior to randomisation),
             unstable angina, New York Heart Association Grade II or greater congestive heart
             failure, or serious cardiac arrhythmia requiring medication

          7. Absolute neutrophil count less than 1500 / mm3

          8. Platelet count less than 100 000 / mm3

          9. Bilirubin greater than 1.5 mg / dl (&gt; 26 micromol / L, SI unit equivalent)

         10. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater
             than 2.5 times the upper limit of normal (if related to liver metastases greater than
             five times the upper limit of normal)

         11. Serum creatinine greater than 1.5 mg / dl (&gt; 132 micromol / L, SI unit equivalent)

         12. Women and men who are sexually active and unwilling to use a medically acceptable
             method of contraception

         13. Treatment with other investigational drugs or in another clinical trial within the
             past two weeks before start of therapy or concomitantly with this trial

         14. Chemo-, hormone, radio- or immunotherapy within the past two weeks before start of
             therapy or concomitantly with this trial

         15. Patients unable to comply with the protocol

         16. Active alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1257.1.4303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1257.1.4302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1257.1.4301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2013</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

